A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
A rapidly degradable tissue adhesive polymer for implantable medical devices
Tissuemed is a Leeds based medical device company, the principal activity of which is the
design, development and manufacture of innovative adhesive medical devices for use in
internal surgical procedures. The devices are based on the company’s proprietary
Tissuebond™ bioadhesive technology and its family of CE marked TissuePatch™ products
are designed to improve clinical outcomes and provide cost benefits to hospitals.
TissuePatch™ is an implantable device, akin to an internal sticking plaster and is used during
surgery to provide a sealing effect that prevents intra and post-operative leaks of air, blood
and CSF fluid.
To open the adhesive polymer technology to new markets, there is a requirement for a novel
second generation tissue adhesive polymer with well-defined and controllable/tuneable
properties to suit the different applications and product requirements of sealant films,
sprayable liquid glues, coated meshes, scaffolds and other medical devices.
The development of a new polymer and implantable medical device is a lengthy process. The
goal of this project is to undertake proof-of-concept synthetic and analytical chemistry
investigations into a novel tissue adhesive. Specifically, this involves the incorporation of
certain chemical functionalities into the polymer structure to enable fine-tuning of
performance and resorption characteristics whilst retaining the superior efficacy properties of
the existing Tissuebond™ polymer and without compromising safety and biocompatibility.
Tissuemed 20JAN15
Tissuemed Ltd is a medical device company based in the North of England, specialising in the manufacture of adherent patches for closure of tissues during surgery.
Development of a bio-resorbable self adhesive support matrix for gastointestinal surgery
Gastrointestinal resections are common general surgical procedures (6 million per year global). Surgery involves cutting out the tumour containing area, with subsequent stitching or stapling of the resected ends to reform the tube, this being defined as an anastomosis. Leakage at the site is a major complication of these operations, with catastrophic patient consequences includi9ng risk of death, coupled with costs of re-operation and intensive care stretching into tens of thousands of pounds. The reported rates of breakdown vary from 1% to 30% dependent on locality and other factors. Good surgical technique alone is also not a predictor of outcome anastomoses failing for a variety of reasons and there being few preventative measures. Surgeons tell us that if they could have a "belt and braces" adjunct to their surgery, "anything that would help them sleep at night" would be welcome. In fact some do use fibrin glues despite a lack of clinical evidence of their efficacy. Tissuemed's tissue sealant technology has been proven in other parts of the study and there are reasoned arguments that it can be modified to provide a support for the healing gut during the critical healing phase. This involves fine-tuning the chemistry to match the characteristics of the tissue, with the associated testing and regulatory work associated with medical device product development. This would be a breakthrough in reducing patient problems, the need for re-operations and associated dramatic costs.